30th Annual Scientific Session and Exhibition of the American Society of Nuclear Cardiology





ASNC 2025

JOIN US IN SUNNY ORLANDO, FLORIDA!

SEPT. 4-7, 2025

Join us at ASNC2025 for the nuclear cardiology event of the year with 60+ expert-led sessions, the Technology and Techniques program on Sept. 13, and much more!

ASNC.ORG/2025

CDL MAKES ADOPTING





724-933-5570 info@cdlnuclear.com www.cdlnuclear.com



Invitation from Your ASNC2025 Program Chairs

Dear Colleagues,

You Are Invited! Please make plans to join us at ASNC's 30th Annual Scientific Session and Exhibition. The Main Program will be held Sept. 4-7 at the Caribe Royale Orlando, a venue popular for convenience, comfort, and proximity to Walt Disney World® Resort, Universal Orlando, and other Florida attractions. ASNC2025 will reconvene on Saturday, Sept. 13, for the Technology and Techniques virtual program.

Enjoy 60+ Innovative and Interactive Sessions! We are looking forward to **welcoming faculty from 94 institutions,** truly representing the world of nuclear cardiology. The program is packed with sessions, events, and career development activities, all reflecting our field's extraordinary growth and the remarkable opportunities before us. **You will find –**

- Clinically driven, case-based tracks and hands-on sessions covering amyloidosis, ischemic heart disease, infection, and inflammation, all showcasing innovations you can use in your practice *now*.
- Heart Team sessions focused on practical, actionable approaches for leveraging nuclear cardiology to inform collaborative decision making. These sessions are a unique opportunity for us to interact with our colleagues at ACC, ASE, EANM, HRS, IDSA, ISA, SCAI, and other sister societies.
- Lab expansion and workflow sessions exploring where emerging technologies, tracers, applications, and AI innovations are leading our field as well as how policy shifts may affect reimbursement, prior authorization, workforce shortages, and more.

Fun and Sun! We look forward to celebrating nuclear cardiology with you at our networking receptions and ASNC's Poolside Party. Plus, stay tuned for details on joining your colleagues for a morning walk or run.

Arrive Thursday! Plan your travel to arrive Thursday, Sept. 4, in time for the pre-conference symposium on launching an F-18 PET perfusion lab, the Opening Reception, and more!

In-person and virtual registration are available; however, the most exciting opportunities almost always happen when we are learning together and connecting in person. **Please join your professional community in Orlando for nuclear cardiology's event of the year.**

See you at ASNC2025!



Wael A. Jaber, MD, FASNC ASNC2025 Program Chair



Paul Cremer, MD, MS ASNC2025 Vice Chair



Alessia Gimelli, MD ASNC2025 International Vice Chair

Program Highlights

Experience ASNC2025 your way whether in person in Orlando or virtually from anywhere!

> Register today to access 60+ cutting-edge sessions, with up to 45^{*} AMA PRA Category 1 Credits[™], Maintenance of Certification (MOC) points, and ARRT Category A credits, disease and case-based tracks, worldclass plenaries, sessions focused on lifelong professional development and growing your lab, as well as the virtual Technology and Techniques program on Sept. 13.

> > New this Year: all attendees receive ASNC2025 Meeting OnDemand, giving you exclusive access to expert-led sessions for two years—through Sept. 2027.

SESSIONS BEGIN AT 2:30PM ON THURSDAY, SEPT. 4

The ASNC2025 Opening Reception will kick off on Thursday evening, setting the stage for an exciting start to the annual meeting!

In addition to the reception, Thursday will feature:



Poster Abstracts – Explore groundbreaking research



Pre-conference Symposium – Launching an F-18 PET Perfusion Lab: Unlock key strategies for clinical implementation, technical optimization, and operational success

Plan to arrive early and be part of this dynamic first day!



Rapid-Fire Sessions – Quick, high-impact insights from experts

ASNC2025 Networking Events



Opening Reception

Thursday, Sept. 4 | 5:30pm-7:00pm

Kick off ASNC2025 with an evening of connection and celebration! Enjoy drinks, hors d'oeuvres, and great conversation as you network with nuclear cardiology leaders, industry partners, and colleagues. Let's set the stage for an unforgettable experience filled with insightful discussions, new collaborations, and lasting connections.



Women in Nuclear (WIN) Cardiology Reception Friday, Sept. 5 | 5:30pm-6:30pm

Celebrate and connect at the Women in Nuclear Cardiology Reception! Join a dynamic gathering of women for an evening dedicated to fostering community, inspiring conversations, and meaningful connections. Don't miss this opportunity to network and champion the future of women in nuclear cardiology.

ASNC Poolside Party

Saturday, Sept. 6 | 8:00pm-10:00pm

Keep the energy going at the ASNC Party! Head to the Calypso and Poolside at the Caribe Royale for a night of music, great food, and lively conversations. Enjoy beats from the DJ, an open beer and wine bar, and delicious bites as you unwind and have fun with colleagues.



There's Only One Standard of Care

for ATTR Cardiac Amyloidosis

- Proven to reduce CV mortality and CV-related hospitalization^{2*}
- Class 1 recommendation for ATTR-CM in the AHA/ACC/HFSA Guidelines^{1†}

There's Only One VYNDAMAX

*VYNDAQEL (tafamidis meglumine) significantly reduced the combination of all-cause mortality and CV-related hospitalizations vs placebo over 30 months, *p*=0.0006. Among patients alive at month 30 (71% pooled VYNDAQEL vs 57% placebo), the average number of CV-related hospitalizations (0.30 vs 0.46) was lower in those treated with VYNDAQEL vs those who received placebo. As individual components of the primary analysis, VYNDAQEL significantly reduced the risk of all-cause mortality (HR, 0.70; 95% CI, 0.51-0.96) and frequency of CV-related hospitalizations (relative risk ratio, 0.68; 95% CI, 0.56-0.81) vs placebo.

vndan

⁺As of September 2024, VYNDAMAX and VYNDAQEL are the only agents approved for ATTR cardiac amyloidosis.



Early diagnosis and treatment of ATTR-CM are important—learn more about VYNDAMAX, the first and only once-daily capsule for adults with ATTR-CM²⁻⁴

INDICATION

VYNDAQEL® (tafamidis meglumine) and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.

IMPORTANT SAFETY INFORMATION

Adverse Reactions

In studies in patients with ATTR-CM, the frequency of adverse events in patients treated with VYNDAQEL* (tafamidis meglumine) was similar to placebo.

Specific Populations

Pregnancy: Based on findings from animal studies, VYNDAQEL and VYNDAMAX may cause fetal harm when administered to a pregnant woman.

Lactation: There are no available data on the presence of tafamidis in human milk, the effect on the breastfed infant, or the effect on milk production. Tafamidis is present in rat milk. When a drug is present in animal milk, it is likely the drug will be present in human milk. Breastfeeding is not recommended during treatment with VYNDAQEL and VYNDAMAX.

AHA=American Heart Association; ACC=American College of Cardiology; ATTR=transthyretin amyloidosis; HFSA=Heart Failure Society of America.

References: 1. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2022;145(18):e895-e1032. 2. VYNDAQEL[®] (tafamidis meglumine) and VYNDAMAX (tafamidis) [prescribing information]. New York, NY: Pfizer Inc. October 2023. 3. Data on file. Pfizer Inc., New York, NY: A. Kittleson MM, Ruberg FL, Ambardekar AV, et al. 2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol*. 2023;81(11):1076-1126.

Please see Brief Summary of Prescribing Information on reverse and Full Prescribing Information, including Patient Information, at VYNDAMAXhcp.com.



VYNDAMAX* (tafamidis) capsules

BRIEF SUMMARY: For full prescribing information, see package insert.

INDICATIONS AND USAGE

VYNDAMAX is indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.

ADVERSE REACTIONS

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The data reflect exposure of 377 ATTR-CM patients to 20 mg or 80 mg (administered as four 20-mg capsules) of tafamidis meglumine administered daily for an average of 24.5 months (ranging from 1 day to 111 months).

Adverse events were assessed from ATTR-CM clinical trials with tafamidis meglumine, primarily a 30-month placebo-controlled trial. The frequency of adverse events in patients treated with tafamidis meglumine 20 mg (n=88) or 80 mg (n=176; administered as four 20-mg capsules) was similar to that with placebo (n=177).

In the 30-month placebo-controlled trial, similar proportions of tafamidis meglumine-treated patients and placebo-treated patients discontinued the study drug because of an adverse event: 12 (7%), 5 (6%), and 11 (6%) from the tafamidis meglumine 80-mg, tafamidis meglumine 20-mg, and placebo groups, respectively.

DRUG INTERACTIONS

BCRP Substrates: Tafamidis inhibits breast cancer resistant protein (BCRP) in humans *[see Clinical Pharmacology (12.3)]*. Coadministration of tafamidis and drugs that are BCRP substrates may increase the exposure of substrates of this transporter (e.g., methotrexate, rosuvastatin, imatinib) and the risk of the substraterelated toxicities. Monitor for signs of BCRP substrate-related toxicities and modify dosage of the substrate if appropriate.

USE IN SPECIFIC POPULATIONS

Pregnancy: Risk Summary Based on findings from animal studies, VYNDAMAX may cause fetal harm when administered to a pregnant woman. However, limited available human data with tafamidis mealumine use in pregnant women (at a dose of 20 mg per day) have not identified any drug-associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes. In animal reproductive studies, oral administration of tafamidis meglumine to pregnant rabbits during organogenesis resulted in adverse effects on development (embryofetal mortality, fetal body weight reduction and fetal malformation) at a dosage providing approximately 9 times the human exposure (AUC) at the maximum recommended human dose (MRHD) of tafamidis meglumine (80 mg), and increased incidence of fetal skeletal variation at a dosage providing equivalent human exposure (AUC) at the MRHD. Postnatal mortality, growth retardation, and impaired learning and memory were observed in offspring of pregnant rats administered tafamidis mealumine during gestation and lactation at a dosage approximately 2 times the MRHD based on body surface area (mg/ m²) (see Data). Advise pregnant women of the potential risk to a fetus. Report pregnancies to the Pfizer reporting line at 1-800-438-1985. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defects, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data In pregnant rats, oral administration of tafamidis meglumine (0, 15, 30, and 45 mg/kg/day) throughout organogenesis resulted in decreased fetal body weights at ≥30 mg/kg/day (approximately 10 times the human exposure at the MRHD based on AUC). The no-observed-adverseeffect-level (NOAEL) for embryofetal development in rats was 15 mg/kg/day (approximately 7 times the human exposure at the MRHD based on AUC). In pregnant rabbits, oral administration of tafamidis meglumine (0, 0.5, 2, and 8 mg/kg/day) throughout organogenesis resulted in increased embryofetal mortality, reduced fetal body weights, and an increased incidence of fetal malformations at 8 mg/kg/day (approximately 9 times the human exposure at the MRHD based on AUC), which was also maternally toxic. Increased incidences of fetal skeletal variations were observed at doses ≥0.5 mg/kg/day (approximately

equivalent to the human exposure at the MRHD based on AUC). In the pre- and postnatal study, pregnant rats received oral administration of tafamidis meglumine at doses of 0, 5, 15, or 30 mg/kg/day throughout pregnancy and lactation (Gestation Day 7 to Lactation Day 20). Decreased survival and body weights, delayed male sexual maturation and neurobehavioral effects (learning and memory impairment) were observed in the offspring of dams treated at 15 mg/kg/day (approximately 2 times the MRHD on a mg/m² basis). The NOAEL for pre- and postnatal development in rats for tafamidis meglumine was 5 mg/kg/day (approximately equivalent to the MRHD on a mg/m² basis).

Lactation: Risk Summary There are no available data on the presence of tafamidis in human milk, the effect on the breastfed infant, or the effect on milk production. Tafamidis is present in rat milk (see Data). When a drug is present in animal milk, it is likely the drug will be present in human milk. Based on findings from animal studies which suggest the potential for serious adverse reactions in the breastfed infant, advise patients that breastfeeding is not recommended during treatment with VYNDAMAX. Data Pregnant and lactating female rats were administered repeated daily oral doses of tafamidis meglumine (15 mg/kg/day) followed by a single oral gavage dose of 14C-tafamidis meglumine on Lactation Day 4 or 12. Radioactivity was observed in milk by 1 hour post-dose and increased thereafter. The ratio of the highest radioactivity associated with ¹⁴C tafamidis meglumine in milk (8 hours post-dose) vs. plasma (1 hour post-dose) was approximately 1.6 on Day 12, indicating tafamidis mealumine is transferred to milk after oral administration.

Females and Males of Reproductive Potential: <u>Contraception</u> Females Based on findings from animal studies, VYNDAMAX may cause fetal harm when administered to a pregnant woman (see Use in Specific Populations). Consider pregnancy planning and prevention for females of reproductive potential.

Pediatric Use: The safety and effectiveness of VYNDAMAX have not been established in pediatric patients.

Geriatric Use: No dosage adjustment is required for elderly patients (\geq 65 years). Of the total number of patients in the clinical study (n=441), 90.5% were 65 and over, with a median age of 75 years.

OVERDOSAGE

There is minimal clinical experience with overdose. During clinical trials, two patients accidentally ingested a single tafamidis meglumine dose of 160 mg without adverse events. The highest dose of tafamidis meglumine given to healthy volunteers in a clinical trial was 480 mg as a single dose. There was one reported adverse event of mild hordeolum at this dose.

NONCLINICAL TOXICOLOGY

Carcinogenesis, Mutagenesis, Impairment of Fertility: Carcinogenesis There was no evidence of an increased incidence of neoplasia in the transgenic (Tg)-rasH2 mouse following repeated daily administration of tafamidis meglumine for 26 weeks at daily doses of 0, 10, 30 or 90 mg/kg. There was no evidence of increased incidence of neoplasia in a 2-year carcinogenicity study in rats at exposures up to 18 times the AUC at the MRHD. Mutagenesis There was no evidence of mutagenicity or clastogenicity in vitro, and an in vivo rat micronucleus study was negative. Impairment of Fertility There were no effects of tafamidis meglumine on fertility, reproductive performance, or mating behavior in the rat at any dose. Rats were dosed daily (tafamidis meglumine 0, 5, 15, and 30 mg/kg/ day) prior to cohabitation (for at least 15 days for females and 28 days for males), throughout the cohabitation period to the day prior to termination of males and through to implantation of females (Gestation Day 7). No adverse effects were noted on male and female rats in toxicity, fertility, and mating behavior at any dose. The paternal and maternal NOAEL for reproductive toxicity of tafamidis meglumine is 30 mg/kg/day, approximately 4 times the MRHD on a mg/m² basis.

This brief summary is based on VYNDAMAX Prescribing Information LAB-0497-6.0.



Distributed by: Parke-Davis Division of Pfizer Inc. New York, NY 10017

Schedule at a Glance

Please use the color bar below to identify ASNC2025 tracks and correlating sessions.

Times in ET	Al, Technology, Tracers & More	A	myloid	Business of Nucl Cardiology	ear	Career Development
THURSD	AY, SEPT 4, 202	5				
12:00pm - 7:00pm			Regi	stration		
2:30pm - 5:30pm	Launch	ning an F an	F-18 PET Per d Operation	fusion Lab: Clin al Consideratio	ical, ns	Technical,
5:30pm - 7:00pm		,	ASNC Recep	otion - Expo Hal	ι	
5:30pm - 6:30pm		Poster A	Abstracts: Iso	chemic Heart Di	seas	ie 1
FRIDAY, S	SEPT 5, 2025					
7:00am - 8:15am		Industry	y Sponsored	l Breakfast Sym	posi	um
8:30am - 10:00am	Plenary: M	lario Ver ar	ani Memoria nd ASNC Awa	ll Lecture, Presi ard Presentatio	dent 1s	ial Addresses,
10:00am - 11:00am	Visit the Expo Hall					
11:00am - 12:00pm	Exhibitor Presentation Ischemic Heart Disease Guidelines and Protocols					
12:15pm - 1:15pm	Industry Sponsored Lunch and Learn					
1:30pm - 2:30pm	Cardiac Sarcoid Connecting the with Advanced Im Modalities In cooperation w the European Assoc of Nuclear Medicing the Heart Rhythm S	osis: Dots aging ith iation e and ociety	Myocardia in the M Harnessing Hardware	al Blood Flow Iodern Era: Software and Innovations	Mc Imp	odern Techniques for proving Image Quality and Interpretation
2:45pm - 3:45pm	Pler In c	ary: Pra	ctice of Nuc n with the Inter	lear Cardiology mational Society of	for A Amy	Amyloid Ioidosis.
3:45pm - 4:45pm	Visit the Expo Hall					
4:45pm - 5:30pm	Exhibitor Present	ation	Decision M Revascu Complex C Imagi In cooper Society for Angiography	Taking Before larization in CAD: How Can ng Help? ation with the Cardiovascular & Interventions	Cu	tting-Edge Research Cardiac Amyloidosis
4:45pm - 5:45pm			Har	nds-on*		
5:30pm - 6:30pm			WIN F	Reception		

*Limited space available for Hands-on sessions. Reserve your spot when you register for ASNC2025.

Hands-on	Industr	y	Infection and Inflammation	lschen Dis	nic Heart sease	Technology and Techniques
		Ra	pid-Fire Session: An	nyloid		
Poster Abstract and Inflam	s: Infection mation		Rapid-Fire Session: Ischemic Heart Disease			Disease
Workflow Ch	Vorkflow Challenges Cases		with the Aces: Endocarditis		F	lands-on*
It Takes Two: Lessons in Mentoring and Being Mentored in Nuclear Cardiology		Is	Cases with the Aces: Ischemic Heart Disease 1 Hands-or		lands-on*	
			Hands-on*			
Poster Abstrac	ts: Amyloid		Rapid-Fire Session	: Al, Techi	nology, Tra	cers & More
Illuminating the Heart: Innovations in Nuclear Imaging Tracers		Speed Mentoring Cases		with the Aces: arcoidosis		

Schedule at a Glance

Please use the color bar below to identify ASNC2025 tracks and correlating sessions.

Times in ET	Al, Technology, Tracers & More	Amyloid	Business of Nuclear Cardiology	Career Development			
SATURDAY, SEPT 6, 2025							
7:00am - 8:15am	Industry Sponsored Breakfast Symposium						
8:30am - 10:00am	Plenary: Imaging for Stable Ischemic Heart Disease: Current Practice and What the Future Holds In cooperation with the American College of Cardiology						
10:00am - 11:00am	Visit the	Expo Hall	Post	er Abstracts: Ischemic H			
11:00am - 12:00pm	Exhibitor Presentation	Challenging Scenarios in Cardiovascular Infection In cooperation with the Society of Cardiovascular Computed Tomography.		Barry L. Zaret Young Investigator Awards Competition			
12:15pm - 1:15pm	Industry Sponsored Lunch and Learn						
1:30pm - 2:30pm	Exhibitor Presentation	The Best of JNC 2024: Nuclear Cardiology Best Practices in Focus	Pathways for Expansion: New Opportunities For Your Nuclear Lab	Finding Your Niche: Directing a Subspecialty Program That Leverages Nuclear Cardiology			
2:45pm - 3:45pm			Plenary: Jeopard	У			
3:45pm - 4:45pm	Visit the Expo Hall Poster Abstracts: Techn			ter Abstracts: Technolog			
4:45pm - 5:30pm	Do We Need AI in Nuclear Cardiology?		Radioactive Revenue: Decoding 2025's Billing Breakthroughs				
4:45pm - 5:45pm	Hands-on*						
8:00pm - 10:00pm	ASNC Poolside Party*						

SUNDAY, SEPT 7, 2025				
7:00am - 8:15am	Industry Sponsored Breakfast Symposium			
8:30am - 10:00am	Plenary: Multimodality Imaging in Endocarditis – Cases with the Experts In cooperation with the American Society of Echocardiography and the Infectious Diseases Society of America			
10:00am - 10:15am	Coffee Break			
10:15am - 11:15am	Ischemia Imaging: Focus on Special Populations			
11:15am - 11:30am	Break			
11:30am - 12:30pm	Patient Journey with Amyloidosis: From Diagnosis to Tracking Response to Therapy			

*Limited space available for Hands-on sessions. Reserve your spot when you register for ASNC2025.

Hands-on	Industry	Infection and Inflammation	lsch I	emic Heart Disease	Technology and Techniques
eart Disease 2		Rapid-Fire Sessi	ion: Inf	ection and In	Nammation
Everything Yo Ask About Runr Lab (But Wer	u Wanted to ning a Nuclear re Afraid To)	Cases with the Aces PET Myocardial Blood F	s: Flow	Ha	ands-on*
Town Hall I on Al in N Cardic	Discussion Nuclear Dlogy	Cases with the Aces Amyloidosis	5:	Ha	ands-on*
		Hands-on*			
y and Tracers		Rapid-Fire Ses	ssion: Is	schemic Heai	t Disease
Beyond the N Through N	White Coat: Too Networking, Adv	ols for Elevating Your Care vocacy, and Social Media	er	Technolo Thriving, N Workforce S Nuclear	ogist Town Hall: ot Just Surviving! olutions for a Busy Cardiology Lab

Schedule at a Glance

Please use the color bar below to identify ASNC2025 tracks and correlating sessions.

Times in ET	Al, Technology, Tracers & More	Amyloid	Business of Nuclear Cardiology	Career Development			
SATURDAY, SEPT 13, 2025 - TECHNOLOGY AND TECHNIQUES (VIRTUAL							
9:00am - 10:00am	PET/CT and SPECT/CT Imaging						
10:00am - 11:00am	D-SPECT for Myocardial Blood Flow: A Viable Alternative to PET?						
11:00am - 11:10am		В	reak				
11:10am - 12:10pm	Be	Conducting High est Practices for Scre	-Quality Exams and eening High Risk Pat	tients			
12:10pm - 1:10pm	What Have	We Learned Using F	-18 Flurpiridaz in PE	T/CT Imaging?			



*Limited space available for Hands-on sessions. Reserve your spot when you register for ASNC2025.



Scan the QR code for the latest program updates.











80 Hour Radionuclide Authorized User TRAINING COURSE

The Course Fellows-in-Training Need to Become an Authorized User of Radioisotopes

The ASNC/SNMMI 80 Hour Radionuclide Authorized User Training Course fulfills the 80 hours of classroom training that the U.S. Nuclear Regulatory

Commission (NRC) and Agreement States require for physicians to become authorized users of radioisotopes for imaging and localization studies.

Advantages You Won't Find Elsewhere:

Get expert-led training from the organizations you trust.

> ORDER NOW

ASNC.ORG/80Hour







CUSTOMER SERVICE TEAM AVAILABLE

STATE-OF-THE-ART LEARNING PLATFORM





The Nuclear Cardiology Knowledge Self-Assessment Program (NCKSAP) is designed for practitioners who are performing nuclear imaging studies and want to increase their competence for certification, recertification, or general practice improvement.

Each module has a total of **30 multiple-choice questions**, includes answer rationales and references, and is available OnDemand for your convenience.

Earn up to 10 CME and 10 MOC points with each module!

General Cardiology as it Relates to Image Interpretation, 4th Edition, Part I	DO	General Cardiology as it Relates to Image Interpretation, 4th Edition, Part II
Ventricular Function, 3rd edition	DO	Nuclear Cardiology Tests/ Procedures/Protocols, 4th Edition
Hybrid Imaging, 1st Edition	DO	Endocarditis, 1st edition
Risk Stratification, 3rd Edition	DO	PET MPI, 1st Edition
Cardiac Amyloidosis, 1st Edition	DO	Radiation Safety, 3rd Edition





ASNC2025 Exhibitor Showcase

ASNC2025 offers many opportunities for meaningful engagement and learning with ASNC's industry partners. Gain valuable insights to maximize the potential of cuttingedge products and services to facilitate lab growth.



Expo Hall Hours:

Thursday, Sept. 4 | 5:30pm – 7:00pm Friday, Sept. 5 | 10:00am – 5:30pm Saturday, Sept. 6 | 10:00am – 5:00pm

Dedicated Expo Hall Hours:

Thursday, Sept. 4 5:30pm – 7:00pm | Opening Reception & Expo

Friday, Sept. 5 10:00am – 11:00am | Expo Break 3:45pm – 4:45pm | Expo Break

Saturday, Sept. 6

10:00am – 11:00am | Expo Break 3:45pm – 4:45pm | Expo Break



Breakfast Symposiums & Lunch and Learns

Dive into thought-provoking discussions on the latest challenges and advancements in nuclear cardiology, while collaborating on innovative solutions. Enjoy a complimentary breakfast and lunch during these sessions on Friday, Saturday, and Sunday.



Cases Over Cocktails

Join us during the Friday afternoon break for a series of engaging case presentations, all while savoring signature cocktails —courtesy of our industry sponsors. Relax, learn, and connect in this informative break session.



Industry Collaboration

This exclusive one-hour interactive breakfast on Friday offers a unique chance to connect with top industry leaders. Move between multiple industry tables, spending up to 10 minutes at each, to gain insights and build valuable relationships. *Invitation only.*



Cardiovascular Imaging **Technologies** Catalyst MedTech

CDL Nuclear

Jubilant Radiopharma

MedTrace Pharma

MIE America

Modern Nuclear

17

Upbeat Cardiology

Special Deals for Attendees

Scan the QR code to access special discounts!





Experience the Magic

No trip to Orlando is complete without a little Disney magic! Explore the iconic **Walt Disney World® Resort**, just a short drive away, where you can dive into in exciting rides, enchanting attractions, and unforgettable entertainment.

Discover Universal Thrills

Step into the action at Universal Orlando Resort, home to **The Wizarding World of Harry Potter, thrilling coasters**, and **captivating movie-themed attractions**. Whether you're a movie buff or a thrillseeker, adventure awaits!

NEW! Universal's EPIC Universe is set

to be the **most immersive theme park** Universal has ever created. Explore five breathtaking worlds, including **Super Nintendo World, The Wizarding World of Harry Potter – Ministry of Magic, How to Train Your Dragon – Isle of Berk, Dark Universe**, and **Celestial Park**. Get ready for next-generation thrill rides, cutting-edge attractions, themed dining, and all-new entertainment in Universal's biggest expansion yet!





Dine, Shop & Stroll at Disney Springs

For a more laid-back experience, visit **Disney Springs**, a lively waterfront district featuring **world-class dining**, **unique shopping**, and **live entertainment**—all with no park ticket required.

Get Wild at Gatorland

Experience Florida's wild side at Gatorland, where you can get up close to alligators, crocodiles, and exotic wildlife in a 110-acre adventure park. Take on the Screamin' Gator Zip Line, see live shows, and even safely walk above alligatorinfested waters on the park's thrilling Stompin' Gator Off-Road Adventure.

Relax, Recharge, and Connect at ASNC2025



Stay with Us at the Caribe Royale Orlando – Your Home for ASNC2025

Experience comfort and convenience at the **Caribe Royale Orlando**, the official venue for ASNC2025. Just minutes from Orlando's top attractions, this **luxurious all-suite hotel** offers spacious accommodations, world-class amenities, and **newly reimagined spaces designed for both work and relaxation**.

Whether you're unwinding by the pool, exploring on-site dining options, or networking in a sophisticated setting, the Caribe Royale sets the stage for an unforgettable experience.



Prime Location – Close to Walt Disney World® Resort, Universal Orlando, and top area hotspots



Exceptional Dining – Indulge in award-winning cuisine without leaving the hotel

Resort Amenities – Spa, fitness center, tropical pool, and more

Book by Aug. 12

to secure exclusive ASNC2025 rates at the Caribe Royale Orlando—rooms starting at \$179/night!

Don't miss out—special discounts end Aug. 12.

ANCORIS DEDICATED CARDIAC PET

ANCORIS

- State-of-the-Art Cardiac PET Powered by Scintron
- Made in Germany
- FDA Cleared
- Windows 10 IoT for the Highest IT Security
- Simultaneous MPI and MFR with List Mode
- Integrated ECG and Respiratory Gating
- Patient Weight up to 500 lbs
- US Sales, Service, and Applications Support







Nuclear Cardiology Board Exam PREP COURSE

Register Now

Prepare for the 2025 CBNC Board Exams and stay updated on nuclear cardiology with ASNC's Nuclear Cardiology Board Exam Prep Course!

Bundle and save—get a special discount when you add the Board Prep Course to your ASNC2025 registration!

The 2025 Board Prep Registration Package includes:



The two-day live, virtual meeting (Sept. 27-28)



4 interactive practice exams with >160 questions





Up to 29.5^{*} CME credits and MOC points and more!

All Board Prep registrants receive two years of OnDemand access (through Sept. 27, 2027) to the prerecorded lectures, interactive practice exams, and virtual-live exam answer explanations by expert faculty.

REGISTER NOW ASNC.ORG/BOARDPREP

*Credit amount subject to change.

ASNC2025 Registration

Your Registration Includes:

- Access to 60+ sessions Sept. 4-7, plus the Technology and Techniques virtual program on Sept. 13
- Convenient, unlimited access to the session recordings on the virtual platform to view any sessions you may have missed
- Up to 45* CME/MOC/CE credits
- NEW! ASNC2025 Meeting OnDemand with two years of access through Sept. 18, 2027

*Credits subject to change.

ASNC2025 In-Person/Virtual Rates

Registration Type				
	Domestic: Physicians, Scientists, and Industry (U.S. and Canada)			
Member	International: Physicians and Scientists			
	Other: Early Career Physicians, Emerging Markets, Technologists, Trainees, Emeritus, Practice Administrators, Associates			
Non- member	Domestic: Physicians, Scientists, and Industry (U.S. and Canada)			
	International: Physicians and Scientists			
	Other: Early Career Physicians, Emerging Markets, Technologists, Trainees, Emeritus, Practice Administrators, Associates			

Early registration ends June 20. Save up to \$200 on your registration!

REGISTER BY
JUNE 20TO SAVE UP TO\$200
ON REGISTRATION!

ASNC.ORG/REGISTER

Members can save even more! For maximum savings, add-on the Board Prep Course to your registration!

ASNC2025 In-Person Registration: Includes all 60+ live sessions in Orlando, Florida, the session recordings on the virtual meeting platform, and the Meeting OnDemand through Sept. 18, 2027. Earn up to 45* CME/MOC/CE credits.

ASNC2025 Virtual Registration: Includes live streaming from the main education rooms, the session recordings on the virtual meeting platform, and the Meeting OnDemand through Sept. 18, 2027. Earn up to **28.25* CME/MOC/CE credits**. (*Note: Not all in-person sessions will be available with virtual registration.*)

Early Rates 2/18-6/20	Advanced Rates 6/21-8/28	On-Site Rates 8/29-9/13
\$799	\$899	\$999
\$499	\$599	\$699
\$249	\$299	\$399
\$1,199	\$1,299	\$1,399
\$699	\$799	\$899
\$399	\$449	\$499

SAVE UP TO **\$200** with Early Registration Rates!



ASNC 2025 JOIN US IN SUNNY ORLANDO, FLORIDA!

ASNC.ORG/2025

SEPT. 4-7, 2025

